SINGLE DOSE DRUG TO TREAT INFLUENZA
There could soon be
a single dose therapy to treat influenza in the US.
Researchers have
found a single injected dose of the neuraminidase inhibitor (NAI) Peramivir to
be safe and effective at alleviating influenza symptoms.
It can palliate
symptoms, including fever and viral shedding, when administered within 48 hours
of the onset of symptoms, an analysis of phase 2 and phase 3 clinical trials
showed.
"Based on
clinical data, Peramivir is the first neuraminidase inhibitor (NAI) that has
shown to be safe and effective as a single dose therapy for patients with
acute, uncomplicated influenza," said Rich Whitley from the University of
Alabama, Birmingham in the US.
In two placebo
controlled studies (one Phase 2 and one Phase 3), involving a combined 427
adults, a single dose of Peramivir was given as an injection within 48 hours of
the onset of flu-like symptoms.
Peramivir was found to be generally safe and
well tolerated and effectively reduced the duration of symptoms in
Peramivir-treated patients.
Compared
to patients who received placebo, Peramivir reduced median time to alleviation
of symptoms by 22 hours, time to resolution of fever by 24 hours and the amount
of nasal viral shedding over the first two days following treatment.
Peramivir
has been approved in Japan and South Korea since 2010.
If
approved by the Food and Drug Administration (FDA), Peramivir would be the only
single dose, injection treatment for influenza in the US and would be the first
NAI approved in more than a decade.
Comments
Post a Comment